FDA — authorised 20 May 2020
- Application: NDA212155
- Marketing authorisation holder: GE HEALTHCARE
- Local brand name: CERIANNA
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA authorised Cerianna on 20 May 2020
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 20 May 2020; FDA has authorised it.
GE HEALTHCARE holds the US marketing authorisation.